Verastem Oncology Q3 Product Revenue Rose to $24.0M
Third-quarter net product revenue was $24.0 million, up from $11.2 million in the year-earlier quarter. GAAP net loss was $74.7 million, or $0.74 per share, versus $98.5 million, or $1.35 per share, a year earlier.
Third-quarter net product revenue was $24.0M, compared with $11.2M in the 2025 quarter. GAAP net loss was $74.7M, or $0.74 per share, versus $98.5M, or $1.35 per share, a year earlier.Material DetailsContext by AI AnalystThis quarter combines commercial progress for the marketed product with increa…